Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma  by Nishio, Makoto et al.
ORIGINAL ARTICLE
Serum Heparan Sulfate Concentration is Correlated with
the Failure of Epidermal Growth Factor Receptor Tyrosine
Kinase Inhibitor Treatment in Patients with Lung
Adenocarcinoma
Makoto Nishio, MD, PhD,* Takeharu Yamanaka, PhD,† Kazuko Matsumoto, MD, PhD,‡
Hideharu Kimura, MD, PhD,‡ Kazuko Sakai, PhD,‡ Asao Sakai, MD, PhD,§
Takashi Sone, MD, PhD,§ Atsushi Horiike, MD,* Fumiaki Koizumi, MD, PhD,
Kazuo Kasahara, MD, PhD,§ Tatsuo Ohira, MD, PhD,¶ Norihiko Ikeda, MD, PhD,¶
Nagahiro Saijo, MD, PhD,# Tokuzo Arao, MD, PhD,‡ and Kazuto Nishio, MD, PhD‡
Introduction: The epidermal growth factor receptor (EGFR) muta-
tion status is a validated biomarker for the stratification of EGFR-
tyrosine kinase inhibitor (EGFR-TKIs) treatment in patients with
non-small cell lung cancer (NSCLC); however, its use is limited in
patients with wild-type EGFR, and new biomarkers are needed. We
hypothesized that the serum concentration of heparan sulfate (HS),
which activates oncogenic growth factor receptor signaling through
EGFR and non-EGFR signaling pathways, may be a novel glyco-
biological biomarker for EGFR-TKIs treatment in NSCLC.
Methods: The pretreatment serum HS concentrations were deter-
mined using enzyme-linked immunosorbent assay in 83 patients
with stage IV non-small cell lung adenocarcinoma who received
EGFR-TKIs treatment. The relationship between the serum HS
concentrations and patient characteristics, tumor response, progres-
sion-free survival (PFS), and overall survival (OS) were analyzed.
Results: Patient sex, performance status, smoking history, and
EGFR mutation status were associated with tumor response. The
serum HS concentrations were significantly higher among patients
with progressive disease than among those without progressive
disease (p 0.003). Furthermore, the serum HS concentrations were
strongly associated with a poor PFS and OS in a univariate Cox
analysis (p  0.0022 and p  0.0003, respectively). A stratified
multivariate Cox model according to the EGFR mutation status
showed that higher HS concentrations were significantly associated
with a shorter PFS and OS (p  0.0012 and p  0.0003).
Conclusion:We concluded that a high-serum HS concentration was
strongly related to a poor treatment outcome of EGFR-TKIs and
may be a promising noninvasive and repeatable glycobiological
biomarker in cancer treatment.
Key Words: Heparan sulfate, Non-small cell lung cancer, EGFR-
tyrosine kinase inhibitors.
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Heparan sulfate proteoglycans (HSPGs) are composed of acore protein and one or more heparan sulfate (HS)
glycosaminoglycan (GAG) chains. Many studies have dem-
onstrated the importance of these molecules in development
and normal physiology including metabolism, transport, in-
formation transfer, support, and regulation at the systemic
level and the cellular level.1 Heparin and HS consist of
repeating disaccharide units that comprised a hexuronic acid
and a D-glucosamine linked to each other and to other
disaccharides by 1A4 linkages.2 The HS component sugars
(N-acetylgalactosamine and -D-glucuronic acid/-L-iduronic
acid) and patterns of sulfating modifications create an ex-
traordinarily large potential for structural diversity.2 The
structural diversity of HS is considered to be important
because HS can bind and interact with a wide variety of
proteins including thrombin, fibroblast growth factors (FGFs)
1 and 2, hepatocyte growth factor (HGF), vascular endothe-
lial growth factor (VEGF), interleukin-8, MIP-1, P-selectin,
laminin, and fibronectin.3 Such interactions are thought to
mediate the enhancement of growth factor/receptor signaling
activity, promote tumor growth, regulate differentiation, in-
duce angiogenesis, modulate host immune cell responses to
tumor cells, and promote metastasis in cancer cells.3 Among
the biological activities of HS, a large body of structural data
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has demonstrated that HS enhances FGFs/FGF receptor sig-
naling by acting as a template that bridges FGF and the FGF
receptor.4 A structure-based proposal for an HS sequence
able to bind FGF and FGFR showed that the interaction
between HS and FGFs or FGFRs seemed to be determined by
a specific sequence of 5-10 saccharides with sulfating mod-
ifications.5 Other growth factor/receptor interactions may
follow a similar binding and activation process. Thus, HS and
HSPG expression may enhance the activity of oncogenic
growth factor receptor signaling in cancer cells.
Meanwhile, selective epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) block EGFR signal
transduction pathways implicated in the proliferation and
survival of cancer cells6–8 and have exhibited clinical activity
against non-small cell lung carcinoma (NSCLC9–11). Several
clinical and molecular biomarkers of EGFR-TKI treatment
have been identified such as gender, smoking status, NSCLC
histology, East Asian ethnicity, and an active EGFR mutation
status that confers constitutively active tyrosine kinase activ-
ity and a hyperresponsiveness to gefitinib among patients
with NSCLC.12,13 These mutations are observed mostly in
either point mutations in exons 18 (G719A/C) and 21 (L858R
and L861Q) or in-frame deletions in exon 19 located at
position 745.14 Two recent phase III trials targeting adeno-
carcinoma in patients with NSCLC with EGFR mutations
have demonstrated that the gefitinib group had a significantly
longer progression-free survival (PFS) than the platinum-
doublet therapy group.15,16 These data indicated that the
EGFR mutation status is a powerful predictor of the tumor
response to EGFR-TKIs.
Recently, we have shown that the serum concentrations
of heparin binding growth factors including heparin-binding
EGF-like growth factor (HB-EGF), HGF, and VEGF are
closely related to the treatment response of EGFR-TKIs in
patients with NSCLC.17 Our results have demonstrated that
the serum concentrations of these growth factors were
strongly related to the outcome of EGFR-TKIs treatment and
suggest that these levels could be used to refine the selection
of patients expected to respond to EGFR-TKIs treatment. On
the basis of these findings, we speculated that the serum
concentration of HS, which activates oncogenic growth factor
receptor signaling through EGFR and non-EGFR signaling
pathways, may be a novel glycobiological biomarker for
EGFR-TKIs treatment in NSCLC. Identifying such a marker
would contribute to the further individualization of treatment
for NSCLC. In this report, we retrospectively studied the
pretreatment serum HS concentrations in patients with stage
IV non-small cell lung adenocarcinoma who underwent treat-
ment with EGFR-TKIs.
PATIENTS AND METHODS
Patients
Pretreatment serum samples from histologically con-
firmed adenocarcinoma and patients with stage IV NSCLC
(n  93) were evaluated in this study. Six patients were
excluded because their tumor response was not evaluated.
Three additional patients were excluded because a complete
clinical data set was not available, and a sufficient serum
sample was not available for one patient. Thus, 83 patients
were included in the final analysis. All the patients had been
treated with EGFR-TKIs (gefitinib, n  78; erlotinib, n  5)
at one of three centers (Kanazawa University, Japan; Cancer
Institute Hospital, Japan; and Tokyo Medical University,
Japan). The tumor response was evaluated every 2 to 3 months
using computerized tomography according to the Response
Evaluation Criteria in Solid Tumors; the response was then
classified as a complete response, a partial response (PR), stable
disease (SD), or progressive disease (PD). Clinicopathological
features including age, sex, Eastern Cooperative Oncology
Group performance status (PS), TNM stage, smoking status and
EGFR mutation status were recorded. To detect active EGFR
mutations, direct sequencing of a tumor sample was performed
in 37 patients; 18 of these samples were found to harbor an
EGFR mutation, whereas the remaining 19 samples exhibited
wild-type EGFR. The mutation status of the other 46 patients
was not evaluated. The median follow-up period was 8.2
months. This study was approved by the institutional review
boards of all the centers involved in the study.
Preparation of Serum Samples
Blood samples were collected before the initiation of
EGFR-TKI treatment. The separated serum was stocked at
80°C until use.
Serum HS Concentrations
Serum HS concentrations were determined using a
human heparan sulfate enzyme-linked immunosorbent assay
(ELISA) Kit (Code. No. 280564; Seikagaku Biobusiness,
Tokyo, Japan). This sandwich-type ELISA kit is composed of
two specific monoclonal antibodies recognizing the disaccha-
ride units of HS. It specifically detects HS but does not
crossreact with heparin, hyaluronic acid, chondroitin sulfate
(CS), or keratin sulfate. In brief, a 50 l aliquot of serum was
treated with 5 l of actinase E at a concentration of 20 mg/ml
at 37°C for 20 hours; the reaction was stopped by heating at
100°C for 5 minutes. The sample was then centrifuged at
10,000 rpm for 10 minutes, and the supernatant (20l) was used
for the analysis. The sample was diluted with 40 l of the
reaction buffer. Then, 20 l of the samples were measured in
duplicate according to the manufacturer’s instructions. The ab-
sorbance of the samples at 450 nm and 630 nm was measured
using VERSAmax (Japan Molecular Devices, Tokyo, Japan).
The average was used for the subsequent analyses.
Statistical Analysis
The primary objective was to investigate novel markers
correlated with treatment efficacy independently of EGFR
status. If a molecule was very strongly associated with sur-
vival after adjustments for the EGFR status and important
prognostic factors, then that molecule was deemed as war-
ranting further prospective study to determine whether it was
a predictive factor, a prognostic factor, or both. The distribu-
tions of the clinical factors were compared between patients
with PD and those without PD using the Fisher’s exact test.
In terms of the analysis for survival time (PFS and overall
survival [OS]), clinical factors including age, sex, Eastern
Cooperative Oncology Group PS, and smoking status were
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examined using the Cox proportional hazards model. After
selecting the important clinical variables, we considered these
variables fixedly in a Cox proportional hazards model and
then determined whether the molecule was associated with
survival independent of the important clinical variables at a
two-sided significance level of 0.05. Log-transformed values
were used for the molecule in the Cox models. The propor-
tional hazards assumption was assessed graphically and using
an individual time-dependent component for each covariate.
In the multivariate Cox models, the EGFR status (wild
type/mutant/unknown) was treated as a stratified variable. We
applied the above analyses to all the cases, to the cases in
which the EGFR status was evaluated, and to the cases with
wild-type EGFR to check the robustness of the conclusions.
The survival curves for PFS and OS were estimated using the
Kaplan-Meier method. All the statistical analyses were per-
formed using SAS for Windows (version 9.1.3).
RESULTS
Patient Characteristics and Tumor Response
The patient characteristics are listed in Table 1. All 83
patients were of Asian ethnicity and had been treated with
EGFR-TKIs (gefitinib, n  79; erlotinib, n  4). Sixty-six
(80%) and four (5%) patients had previously received che-
motherapy and radiotherapy, respectively. Nineteen patients
had wild-type EGFR, 18 had active mutations (exon 19, n 
13 and exon 21, n  5), and 46 had an unknown status
because their samples had been collected before the identifi-
cation of this biomarker.12,13 Regarding the response to
EGFR-TKIs treatment, a PR was observed in 34 (41%)
patients, SD was observed in 20 (24%) patients, and PD was
observed in 29 (35%) patients; none of the patients exhibited
a complete response. Significant differences in the tumor
response were observed for patients characteristics such as a
sex (p  0.0002), PS (p  0.04), smoking history (p 
0.003), and EGFR status (p  0.00001). These findings were
consistent with those of many previous reports.
Serum Concentrations of HS and Tumor
Response
The serum concentration of HS ranged from 3.3 to 85.8
g/ml in all the patients (Table 1) and were over 20 g/ml in
13 patients, indicating the presence of large individual dif-
ferences in serum HS concentration. The serum HS concen-
tration is shown for the tumor response groups in Figure 1. Of
note, the serum HS concentration was significantly higher
among patients with PD (22.2  23.1 g/ml) than among
those without PD (10.9  9.8 g/ml, p  0.003). The
sensitivity and specificity of HS for discriminating PD from
PR  SD were determined using the optimal cutoff value
(13.5 g /ml) obtained from a receiver operating character-
istic (ROC) curve according to a previous report.17 The
sensitivity and specificity of HS for discriminating PD from
PR  SD were 0.448 and 0.851, respectively.
Univariate Analysis of Clinical Molecular
Factors for PFS and OS
The median PFS and OS were 4.1 and 10.2 months,
respectively. Among the clinical factors that were examined,
a male sex, a positive smoking history, and a poor PS were
significantly related with a poor PFS and OS (Table 2). A
higher serum HS concentration was significantly associated
with a shorter PFS (HR, 3.61; p 0.0022) and OS (HR, 5.57;
p  0.0003; Table 2). Thus, similar to the results for tumor
response, a high serum HS concentration was closely asso-
ciated with a poor EGFR-TKIs treatment outcome.
Figures 2A, B shows the Kaplan-Meier estimates for
PFS and OS with respect to the concentrations of serum HS.
All the patients were divided into two groups according to the
cutoff value (13.5 g /ml) described earlier. The curves
indicated that the high serum HS group had a significantly
poorer treatment outcome with respect to both PFS (median,
47 versus 161 days; p  0.002) and OS (median, 105 versus
406 days; p  0.0002).
Multivariate Analysis of Clinical Molecular
Factors for PFS and OS
As the EGFR status of half the patients in this study
was unknown, we used a stratified multivariate Cox analysis
TABLE 1. Patient Characteristics, Serum Concentration of
Heparan Sulfate, and Response to EGFR-TKIs
Total
(n  83) (%)
Response
p
PR  SD
(n  54)
PD
(n  29)
Age (yr) 0.65
65 43 (52) 27 16
65 40 (48) 27 13
Sex 0.0002
Male 46 (55) 22 24
Female 37 (45) 32 5
PS 0.04
0–1 60 (72) 43 17
2–4 23 (28) 11 12
Smoking 0.003
Yes 51 (61) 27 24
No 32 (39) 27 5
CTx 0.27
Yes 66 (80) 41 25
No 17 (20) 13 4
RTx 0.08
Yes 4 (5) 1 3
No 79 (95) 53 26
EGFR status 0.00001a
Wild 19 (23) 6 13
Mutant 18 (22) 18 0
Unknown 46 (55) 30 16 —
HS
Range 3.3–85.8 3.3–51.0 3.8–85.8
Mean  SD 14.9  16.5 10.9  9.8 22.2  23.1 0.003
p values are calculated using the t test for serum concentration of heparan sulfate
and the Fisher’s exact test for other variables.
a Comparison between wild type and mutant.
HS, serum concentration of heparan sulfate (g/ml); PR, partial response; SD,
stable disease; PD, progressive disease; PS, performance status; EGFR-TKIs, epidermal
growth factor receptor tyrosine kinase inhibitors; CTx, prior chemotherapy; RTx, prior
radiotherapy; —, not done.
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that included the EGFR status as a stratification factor18
(Table 3). First, sex and PS remained statistically significant
at a level of 0.05 in a multivariate model after backward
selection. The smoking status was no longer significant (p 
0.46 and p  0.40 for PFS and OS, respectively) because it
was highly correlated with sex (p  0.0001, Fisher’s exact
test). Thus, we used sex and PS as fixed factors in the Cox
model. The serum HS concentration was significantly corre-
lated with poor treatment outcomes for PFS (HR 3.98, p
0.0012) and OS (HR  5.42, p  0.0003) in the final model;
a high concentration of HS was correlated with a shorter PFS
and OS independently of the EGFR status, sex, and PS (Ta-
ble 3). In the final model, no interaction was shown between the
EGFR status and the serum HS concentration (p 0.20 for both
PFS and OS). The results presented in Table 3 were also
stable in analyses of subsets of patients with a known EGFR
status as well as patients with wild-type EGFR (data not
shown). Regarding EGFR mutations and the HS concentra-
tion, we verified the results in additional experiments using
an independent set of 48 serum samples from patients
whose tumor EGFR status was known. The results showed
that a high serum HS level was reproducibly associated
with a poor PFS during EGFR-TKI treatment, although the
p value was not significant (p  0.087, Supplementary
Figure 1A, http://links.lww.com/JTO/A109). The EGFR
status did not seem to be associated with the serum HS
concentrations in the 48 additional samples (p  0.48, Sup-
plementary Figure 1B, http://links.lww.com/JTO/A109).
Taken together, these observations suggested that a
high serum HS concentration was significantly associated
with the failure of EGFR-TKIs treatment and may be a novel
glycobiological biomarker.
DISCUSSION
The major GAG in the blood is CS, and other serum
GAGs include HS, keratin sulfate, and hyaluronan.19 Many
methods are now available to measure the concentration of
serum/plasma GAGs; these methods include cellulose acetate
membrane electrophoresis, paper, affinity, and gas chroma-
tography, capillary electrophoretic analysis, and HPLC. Nev-
ertheless, no standardized methods exist for serum/plasma
GAG isolation and quantification.19 Our approach using a
sandwich ELISA was easy to perform, quantitative, and
reproducible. The C.V. value was below 10% in intraplate,
intrakit, and intraday analyses (data of Seikagaku-kogyo).
Regarding individual differences, the Alcian blue dot blot
method showed that the GAG concentration of plasma from
hospitalized patients exhibited a variation of plasma GAGs of
0.1 to 17.6 g/ml,20 and our result for the HS concentration
was 3.3 to 85.8 g/ml. Identifying the cause of these indi-
vidual differences will require further study. Recent studies
have shown that the pleural fluid/serum GAG ratio may be
useful for the simultaneous differentiation of exudates from
transudates and of malignant exudates from benign exu-
dates.21 In ovarian cancer, the serum CS level may be useful
as a discriminator between benign ovarian disorders and
malignant ovarian diseases.22
Accumulating evidence has demonstrated that HSPG
has oncogenic roles in cancer cells. Perlecan is a potent
inducer of bFGF-mediated neovascularization in vivo.23 In
addition, several studies have shown that large deposits of
perlecan were observed in the tumor stroma and blood vessel
walls in liver tumor and invasive breast cancer in clinical
specimens.24,25 The strong reactivity for perlecan in tu-
moral stromal vessels suggests a role for these HSPGs in
tumoral angiogenesis, and the angiogenic effect is considered
to interact with various proangiogenic ligands.26 On the other
hand, high expression levels of shed/soluble syndecans-1 are
found in the serum of patients with myeloma and lung cancer,
FIGURE 1. Box-whisker plots of serum HS concentration in
patients with a partial response (PR, n  34), stable disease
(SD, n  20), and progressive disease (PD, n  29). HS, se-
rum concentration of heparan sulfate (g/ml). *Progressive
disease (PD) versus PR  SD, p  0.05.
TABLE 2. Univariate Analysis of Clinical and Molecular
Factors for Progression-Free Survival and Overall Survival
PFS OS
Log Rank,
p
Cox
Log Rank,
p
Cox
HR p HR p
Age (yr)
65 vs. 65 0.678 0.91 0.6791 0.978 0.99 0.9777
Sex
Male vs. female 0.002 2.08 0.0026 .0001 3.06 0.0001
Smoke
Yes vs. no 0.024 1.74 0.0257 0.011 1.99 0.013
PS
2–4 vs. 0–1 0.075 1.56 0.079 0.002 2.31 0.0021
HS
Continuous n.d. 3.61 0.0022 n.d. 5.57 0.0003
Univariate analyses of factors for progression-free survival (PFS) and overall
survival (OS) were for all the patients. Log-transformed values were used for all the
molecules.
HR, hazard ratio; n.d. not done; HS, serum concentration of heparan sulfate
(g/ml); PS, performance status.
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and these high expression levels were predictors of a poor
prognosis.27,28 Compared with the normal form of synde-
cans-1, the shed form of syndecans-1 gains oncogenic func-
tions leading to hyperinvasiveness and the increased tumor
growth of myeloma tumors in vivo.29 Thus, shed HSPGs
remain highly biologically active and can regulate cell growth
and metastasis in cancer.30 In line with this observation, our
findings that a high HS expression level was correlated with a
poor clinical outcome may be associated with the expression of
the shed/soluble form of HSPGs. Regarding the correlation
between the HS expression levels in tumor and serum samples,
we examined the HS expression levels in 10 independent pairs
of serum and surgical samples. Representative results of the
immunostaining for tumor HS expression are shown in Supple-
mentary Figure 2 (http://links.lww.com/JTO/A110). An anti-HS
antibody was used in this experiment with or without hepa-
ritinase I digestion. Heparitinase I digestion completely abol-
ished the staining (left panel). Under such conditions, HS was
strongly expressed on the membranes of lung cancer cells
(lower right panel). Furthermore, HS expression in the tumor
tissues was relatively weak in all five cases in the group with
a low serum HS level (lower panel, Supplementary Figure 3,
http://links.lww.com/JTO/A111), whereas strong HS expres-
sion in the tumor tissues was observed in three of the five
cases in the group with a high serum HS level (upper panel,
Supplementary Figure 3). These results suggested that the
tumor and serum HS expression levels may be positively
correlated.
The activation of EGFR signaling occurs as a result of
mutations affecting the adenosine triphosphate-binding cleft
of EGFR, and EGFR mutants exhibit constitutive tyrosine
kinase activity independently of any ligand. We found that
the serum HS concentration was significantly higher among
patients with PD and was strongly associated with a poor PFS
and OS in EGFR-TKIs-treated patients. No difference in the
serum HS concentration was observed between the PR and
SD groups, but a difference was seen between the PD and
non-PD groups (Figure 1). Therefore, the serum HS concen-
tration may be involved in drug resistance but not in sensi-
tivity. Regarding resistance to EGFR-TKIs treatment, the
amplification of met proto-oncogene (MET) causes gefitinib
resistance by driving the v-erb-b2 avian erythroblastic leuke-
mia oncogene homolog 3 (ERBB3)-dependent activation of
phosphoinositide-3-kinase, and previous authors have pro-
posed that MET amplification may promote drug resistance in
other ERBB-driven cancers.31 Yano et al.32 showed that HGF-
mediated MET activation is involved in gefitinib resistance in
lung adenocarcinoma with EGFR-activating mutations. A recent
study has clearly demonstrated that HGF accelerates the devel-
FIGURE 2. Kaplan-Meier curves for progression-free survival (PFS) and OS according to serum concentrations of heparan sul-
fate (HS). Optimal cutoff point (13.5 g/ml) of serum HS was determined from a receiver operating characteristic (ROC)
curve to discriminate progressive disease (PD) or without PD. Kaplan-Meier curves for PFS (A) and OS (B) are shown. HS high,
patients with a serum HS concentration 13.5 g/ml. HS low, serum HS concentration 13.5 g/ml.
TABLE 3. Final Multivariate Model for Progression-Free
Survival and Overall Survival
PFS OS
HR p HR p
Sex
(male vs. female) 1.82 0.0231 2.43 0.0031
PS
(2–4 vs. 0–1) 1.09 0.7610 1.95 0.0235
HSa 3.98 0.0012 5.42 0.0003
Sex and PS were fixed in the model. Molecular markers were then selected using
the backward selection procedure with a removal probability of 0.05. In all the steps, a
Cox model stratified according to the EGFR status (wild type/mutant/unknown) was
applied.
a Log-transformed values are used for HS.
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; EGFR,
epidermal growth factor receptor; HS, serum concentration of heparan sulfate (g/ml);
PS, performance status.
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opment of MET amplification both in vitro and in vivo, medi-
ating the EGFR kinase inhibitor resistance caused by either
MET amplification or autocrine HGF production.33 These stud-
ies indicate that the activation of HGF-MET signaling confers
resistance to EGFR-TKIs. Our previous study also showed that
a high concentration of serum HGF is a predictive biomarker for
EGFR-TKIs treatment.17 Therefore, the activation of HGF-MET
signaling in lung cancer cells is considered to be a cause of drug
resistance to EGFR-TKIs. In addition, combined with data on
the serum HGF, VEGF, HB-EGF, and PDGF-BB levels from a
previous study,17 the correlation coefficient between the serum
HS and the HGF, VEGF, HB-EGF, and PDGF-BB levels were
0.45, 0.46, 0.03, and 0.13, respectively. These results indi-
cated that the expression pattern of the serum HS level was
weakly similar to those of the HGF and VEGF levels but was
not correlated with the HB-EGF or PDGF-BB levels.
In this study, the serum HS concentration was identified
as another candidate biomarker for treatment resistance, and
this finding may provide novel glycobiological insight into
drug resistance to EGFR-TKIs. The results suggest that a
high serum HS concentration may be related to the activation
of non-EGFR signaling, such as HGF, FGF, and VEGF
signaling in cancer cells. We plan to conduct a prospective
study to validate the ability of the serum HS concentration to
predict the response to EGFR-TKIs treatment.
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